Can MRK's Ongoing M&A Push Aid Long-Term Growth Ahead of Keytruda LOE?

Merck completed a $6.7B acquisition of Terns as part of a broader M&A spree to diversify its pipeline and revenue base. The transactions are positioned to mitigate concentration risk as Keytruda approaches loss of exclusivity in 2028.

Analysis

Merck completed a $6.7B acquisition of Terns as part of a broader M&A spree to diversify its pipeline and revenue base. The transactions are positioned to mitigate concentration risk as Keytruda approaches loss of exclusivity in 2028.